Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Compugen Announces Development of NexGen Infrastructure

Published: Tuesday, July 03, 2012
Last Updated: Tuesday, July 03, 2012
Bookmark and Share
New platform significantly enhances drug and target discovery potential of Compugen's LEADS and MED platforms.

Compugen Ltd. has announced the development of "NexGen," a new platform designed to significantly enhance Compugen's overall infrastructure for predictive drug and drug target discovery. NexGen is designed to analyze Next Generation Sequencing data which is now beginning to be generated worldwide through RNA-Seq methodology. RNA-Seq is a new and powerful ultra-high throughput approach to provide raw data for transcriptome analysis and expression profiling. Although this new approach provides a massive amount of data in the form of very short partial transcript sequences, it also creates an extremely challenging environment for obtaining meaningful and accurate information.

Compugen's NexGen Platform, which incorporates advanced algorithms and other proprietary tools, is designed to efficiently and accurately integrate and analyze this vast amount of short sequence data. The integration of this capability with Compugen's discovery infrastructure, mainly its predictive transcriptome and proteome, is expected to provide the Company with both enhanced identification of novel genes and splice variants, and a broader view of the expression levels of RNA transcripts, facilitating new associations to pathological or healthy conditions. These new integrated capabilities should provide Compugen with further substantial advantages in predictive discovery of potential drugs and drug targets, and also in the discovery of potential diagnostic product candidates.

The proprietary insights obtained by Compugen's decade-long pioneering research focused on predictive transcriptome and expression analysis, which resulted in the Company's LEADS and MED platforms, were fundamental in overcoming the technological challenges in building the NexGen platform. In turn, by enabling the integration and analysis of this enormous quantity of additional data, the NexGen platform adds significant advantages to LEADS and MED, the infrastructure platforms that support all of Compugen's drug and target product candidate discovery platforms. Similar to the LEADS and MED platforms, NexGen is broadly applicable across essentially all therapeutic and diagnostic areas, but its primary use will be in support of the Company's focus areas of novel therapeutic proteins and monoclonal antibodies for oncology and immunology, highly complex therapeutic areas with significant unmet medical needs.

Dr. Zurit Levine, Compugen's VP of Research and Discovery, stated, "New RNA-seq high-throughput sequencing techniques are beginning to generate vast quantities of data that provide a potentially invaluable, but difficult to utilize, resource for use in the discovery of drugs and diagnostics. This is particularly true with respect to complex diseases such as cancer and immune-related pathologies. Therefore, our successful development of the NexGen platform, built on, extending and enhancing our existing predictive capabilities, represents an important addition to our infrastructure for internal discovery as well as for discovery collaborations with others."

Dr. Anat Cohen-Dayag, President and CEO of Compugen, added, "NexGen is an excellent example of how Compugen benefits on an ongoing basis from our decade-long and continuing pioneering efforts to create deeper scientific understandings, algorithms, and approaches for predictive modeling of key biological phenomena at the molecular level. Built from the "bottom up," our unique predictive discovery infrastructure can readily integrate new technologies such as RNA-seq, as part of the process by which this infrastructure is continuously enhanced and expanded."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Compugen Appoints Martin Gerstel CEO Effective January 2009
Mr. Gerstel, who has served as chairman of Compugen since 1997, will succeed current president and chief executive officer Mr. Alex Kotzer.
Friday, November 14, 2008
Scientific News
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
On Top of the Flu
Chance for advance warning in search-based tracking method.
TGAC Announces Milestone in Wheat Research
A more complete and accurate wheat genome assembly is being made available to researchers, by The Genome Analysis Centre (TGAC) on 12 November 2015.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.
Questioning the Validity of Forensic DNA Match Statistic
Fifteen years of criminal cases with affected mixture evidence.
Predicting Adverse Drug Reactions with Higher Confidence
A new integrated computational method helps predicting adverse drug reaction—which are often lethal—more reliably than with traditional computing methods.
Healthcare and Life Sciences, Meet the Third Platform of Storage
Current EHR solutions are good for capturing and organizing patient information within a hospital environment, but they are not designed to organize data across the many systems.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos